Preventing Neutropenic Complications
|
|
- Oscar Lane
- 6 years ago
- Views:
Transcription
1 Preventing Neutropenic Complications Michael Rader, MD Clinical Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack Hospital Instructions While viewing this presentation, you can control the slides by using the next and previous controls. When using the audio format, a play/pause button is also available. You can also jump to a specific slide using the thumbnail. You can zoom into the slides by clicking the enlarge slide button. Then, click the slide to return it to its normal size.
2 Instructions To bookmark a slide in the presentation for later review, click the Bookmark Slide button. You can then view your remembered slides on the Bookmarks tab. You can save as many slides as you would like. If you would like to write notes while viewing the presentation, click on the Notes tab. You are given the option to add notes and print notes. You can pause the audio presentation while you compose your notes. Michael Rader, MD Clinical Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack Hospital
3 Educational Objectives Discuss the incidence of febrile neutropenia to have a better understanding of its frequency. Verify the importance of administering GSF in the first cycle of chemotherapy to reduce the risk of febrile neutropenia. According to NCCN Guidelines, outline the appropriate utilization of GSF in febrile neutropenia. Risk of Chemotherapy Induced Neutropenia Increases risk of febrile neutropenia Life threatening infections Hospitalization Increased Cost Suboptimal chemotherapy dosing Leading cause of dose reductions May impair quality of life Significance and incidence not always appreciated
4 Case 1 Patient is a 66 year old female who presents with a mass in her right neck which she has noted over the past month Patient was seen by her primary care physician who prescribed an antibiotic for ten days When the lymph node failed to shrink, she was sent for surgical evaluation Patient denies fever, chills sweats or weight loss Patients appetite is good Case 1 (continued) Patient s past medical history is positive for hypertension for the last five years Patient has type II diabetes for which she takes metformin Patient smokes 2 packs per day for the last 29 years and has been diagnosed with COPD Patients family history is noncontributory Patient does clerical work Review of systems is significant for a persistent cough which has been present for several years and she has associated with smoking
5 Case 1 Physical Examination and Laboratory Evaluation Physical Examination revealed a well nourished, well developed female in no acute distress Examination of the head, eyes, ears nose and throat is unremarkable. Patient has a 2 by 3 cm left cervical node Patient has several 1 x 1 cm axillary lymph nodes and a 2 x 3 cm left inguinal node Chest show occasional rhonchi The heart is regular with no murmurs, gallops or rubs Abdomen reveals no organomegaly Case 1 Physical Examination and Laboratory Evaluation (continued) Rectal and genital examination is unremarkable Breasts are normal and patient is neurologically intact Skin and extremities are unremarkable Patients WBC is 5400, Hb 10.3, Hct 31.2% and platelet count is 234,000 A complete metabolic profile reveals an LDH of 600 Albumin and total protein is normal Patient is sent for lymph node biopsy
6 Case 1 Workup Biopsy reveals a diffuse large cell lymphoma Staging is done PET CTT scan reveals FDG uptake in the cervical, axillary, paraortic and inguinal regions, Spleen and liver are normal No other abnormalities are noted Patient is felt to have Stage III A large cell lymphoma Patient is begun on rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone every 21 days Question 1 When is this patient at greatest risk of developing febrile neutropenia? a. Cycle 2 b. This patient is not at risk for febrile neutropenia c. Cycle 1 d. Risk increases each cycle and is higher in the last cycle
7 Answer 1 When is this patient at greatest risk of developing febrile neutropenia? a. Cycle 2 b. This patient is not at risk for febrile neutropenia c. Cycle 1 d. Risk increases each cycle and is higher in the last cycle Severe Neutropenic Events Occur in Many Types of Tumors 60 Patients (%) % 43% 42% 30% N = % 10 0 Breast Lymphoma Ovarian Lung Colon ANC < 0.5 x 10 9 /L and neutropenic complications such as fever, infection, etc Crawford J, et al. Poster presented at: 16 th MASCC/ISOO International Symposium; June 24-27, 2004; Miami Beach, Fla.
8 Most Neutropenic Events Occur in the First Cycle of Therapy Cycle 1 Cycle 2 Cycle 3 Cycle 4 Patients with initial neutropenia (%) N = Crawford J, et al. Blood. 2004;104:11. Abstract Chemotherapy Induced Neutropenia is the Major Cause of Dose Delays and Reductions Reason for Dose reduction 46% 44% 54% 56% Neutropenia Related Other Causes Reason for dose delay 42% 58% 41% 59% Early Stage Breast Cancer (n=436) Link BK, et al. Cancer. 2001;92: Picozzi VJ, et al. Oncology. 2001;15: Non-Hodgkin's Lymphoma (n=235)
9 Question 2 According to current NCCN guidelines R- CHOP has an incidence of febrile neutropenia between 10 and 20%? a. True b. False Answer 2 According to current NCCN guidelines R- CHOP has an incidence of febrile neutropenia between 10 and 20%? a. True b. False The NCCN guidelines state that RCHOP has a febrile neutropenia rate between 10 and 20% NCCN Guidelines V. 2006
10 Predicted Probability of Infection vs. Duration of Febrile Neutropenia (ANC< 500), Cycle 1 Predicted probability of Febrile neutropenia Predicted probability Days of Neutropenia Adapted from Blackwell S, Crawford J. In: Morstyn G, Dexter TM, eds. Filgrastim (r-met HuG-CSF) in Clinical Practice. New York, NY: Marcel Dekker; 1994: ; Crawford J, et al. N Engl J Med. 1991;325: Benefit of CSF at a 20% Febrile Neutropenia Rate Objective was to show that first and subsequent cycle pegfilgrastim reduced FN in a regimen associated with an expected FN incidence of ~ 20% Docetaxel 100mg/m2 IV every 3 weeks in patients with breast cancer was chosen as a representative clinical setting Double blind, randomized placebo control, multicenter First cycle pegfilgrastim or placebo day 2 Stratification by disease state Chemotherapy planned for 4 cycles Vogel et al. J Clin Oncol. 2005;23:
11 Incidence of Febrile Neutropenia 20 N = % Reduction P <.0001 Odds Ratio: 15.02* FN rate (%) n = 465 Placebo 1 n = 463 Pegfilgrastim *95% CL, 6.51, Vogel C, et al. J Clin Oncol. 2005;23: FNH rate (%) Febrile Neutropenia Related Hospitalizations N = Placebo * 95% CL, 5.17, % Reduction 1 n = 465 n = 463 P <.0001 Odds Ratio: 11.99* Pegfilgrastim Vogel C, et al. J Clin Oncol. 2005;23:
12 Febrile Neutropenia Related IV Antiinfective Use IV anti-infective use (%) N = n = 465 n = 463 Placebo 80% Reduction P <.0001 Odds Ratio: 7.47* Pegfilgrastim * 95% CL, 3.35, Vogel C, et al. J Clin Oncol. 2005;23: Incidence of Neutropenia, by Cycle The incidence of grade 3 (hatched bars) and grade 4 (solid bars) neutropenia was markedly reduced for patients receiving pegfilgrastim across all cycles. Incidence (%) Placebo Pegfilgrastim n = 465 n = 454 n = 438 n = 413 n = 463 n = 458 n = 445 n = 427 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Vogel C, et al. J Clin Oncol. 2005;23:
13 Febrile Neutropenia, by Cycle In the placebo group, 65% of febrile neutropenic events occurred in the first cycle. Patients With Febrile Neutropenia (%) Placebo, n = 465 Pegfilgrastim, n = % 6% <1% <1% Cycle 1 Cycles 2 to 4 Vogel C, et al. J Clin Oncol. 2005;23: Colony-Stimulating Factor Prophylaxis: Updated NCCN Guidelines Febrile Neutropenia Risk High (>20%) Intermediat e (10%-20%) Low (<10%) Curative/ Adjuvant Use CSF Consider CSF CSF not recommended Treatment Intent Prolong Survival/QOL Use CSF Consider CSF CSF not recommended Symptom Management/QOL Use CSF Consider CSF CSF not recommended QOL = quality of life; CSF = colony-stimulating factor. NCCN. Myeloid Growth Factors in Cancer Treatment. Version
14 Question 3 What are this patients risk factors for developing febrile neutropenia? a. Female Gender b. Diabetes Mellitus c. Age d. COPD e. All of the above f. a, b, d NCCN. Myeloid Growth Factors in Cancer Treatment. Version Answer 3 What are this patients risk factors for developing febrile neutropenia? a. Female Gender b. Diabetes Mellitus c. Age d. COPD e. All of the above f. a, b, d NCCN. Myeloid Growth Factors in Cancer Treatment. Version
15 Explanation Question 3 The NCCN guidelines have identified risk factors which influence the risk of febrile neutropenia These risk factors are Treatment related :Drugs (esp. anthracyclines), treatment intent (rdi>80%), regimen, prior neutropenia or lymphocytopenia, prior chemotherapy, prior RT Patient related: Age >65, female gender, poor performance status, poor nutrition decreased immune function Comorbidities: COPD, Cardiovascular disease, liver disease,, diabetes mellitus anemia Cancer related: Bone Marrow involvement, uncontrolled cancer, elevated LDH, leukemia, lymphoma. Lung cancer Growth Factor Support Evaluate Assess risk Intervene Disease Regimen Patient Risk Factors Treatment Intent High >20% risk Intermediate 10-20% risk Low <10% risk Use G-CSF Consider G-CSF No routine G-CSF
16 Case 3 56 year old female presents with a 3cm mass in her left breast Patient is in otherwise good health except for hypertension Physical examination reveals a 3cm mass in the right breast Axiliary examination is normal Patient underwent a left segmental mastectomy An infiltrating ductal carcinoma was diagnosed Case 3 (continued) The tumor was noted to be estrogen receptor, progesterone receptor and Her-2 negative Axillary node dissection reveals 4 of 10 positive lymph nodes Patient elected to receive dose dense chemotherapy with cyclophosphamide 600mg/m2, doxorubicin 60mg/m2 every two weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles This is to be followed by radiation therapy
17 Question 1 Which of the following statements are correct? a. Patient does not need growth factors for this regimen b. CSF should be administered for five days post each cycle of chemotherapy c. You cannot use pegfilgrastim in this regimen since the intervals between cycles is to short d. None of the above e. All of the above Question 1 Which of the following statements are correct? a. Patient does not need growth factors for this regimen b. CSF should be administered for five days post each cycle of chemotherapy c. You cannot use pegfilgrastim in this regimen since the intervals between cycles is to short d. None of the above e. All of the above
18 Explanation Question 3 Dose dense chemotherapy cannot be given without growth factor support. Indeed, the NCCN guidelines call for CSF beginning with the first cycle of chemotherapy when the intent of treatment is to provide a relative dose intensity of 80% or greater. Hudis et al have shown that figuratum 5 micrograms per kilogram on days 3-10 following dose dense chemotherapy reduced febrile neutropenia to 2-3%. Hudis et al. Journal of Clinical Oncology, Vol 17, Issue 1 (January), 1999: 93 Burstein et al. San Antonio Breast Conference 2004 Abstract1055 Yang et al. ASH 2003 Abstract 1918 Explanation Question 3 (continued) Burstein et al. showed that of 135 patients receiving this regimen treated with pegfilgrastim 6mg on day 2 only two developed febrile neutropenia. The rate was 1.5% with dose on time being 88.4%. The concentration of pegfilgrastim in the serum is mediated by neutrophil clearance. At a post nadir ANC greater > t 1000, pegfilgrastim serum concentration is <2ng/ml, allowing for the next cycle of chemotherapy.
19 Case 2 45 year old female has Stage II breast cancer. This was found on routine mammography. Tumor was an intraductal carcinoma, grade 3, 2 out of 12 lymph nodes positive. Estrogen and progesterone receptors are both positive (95% each) and her-2 is negative. Patient undergoes lumpectomy and axillary node dissection after having a positive sentinal node. Case 2 (continued) Physical examination is remarkable for a scar at the site of her surgery. The remainder of the examination is normal. Laboratory examination reveals a normal CBC and normal liver function studies. Following surgery, the patient opts for chemotherapy with TAC. (Taxotere 75 mg/m2, Adriamycin and Cytoxan) followed by radiation therapy and hormonal therapy.
20 Question 1 The appropriate method to lower the risk of febrile neutropenia would be: a. Pegfilgrastim 6 mg 24 hours post chemotherapy b. Antibiotic prophylaxis with a quinolone antibiotic c. Filgrastim or Sargramostim beginning 24 hours after chemotherapy given until after nadir d. Filgrastim for 5 days beginning day 5 e. a and c Question 1 The appropriate method to lower the risk of febrile neutropenia would be: a. Pegfilgrastim 6 mg 24 hours post chemotherapy b. Antibiotic prophylaxis with a quinolone antibiotic c. Filgrastim or Sargramostim beginning 24 hours after chemotherapy given until after nadir d. Filgrastim for 5 days beginning day 5 e. a and c
21 GEICAM 9805 Safety Analysis Confirms Benefit of First Cycle Use of G-CSF Patients (%) % Gr 3-4 Neutropenia 40.9% Pre-amendment TAC (no first-cycle G-CSF; n=109) Post-amendment TAC (first- and subsequent cycle G-CSF; n=115) 23.9% P< % Febrile Neutropenia* *Grade 2 fever ( 38.5 o C) with grade 4 neutropenia and requiring IV antibiotics and/or hospitalization in the same cycle. *TAC: docetaxel, doxorubicin, cyclophosphamide Martin M, et al. Proc. Am. Soc. Clin. Oncol. 2004:22-23 Abstract and Poster Primary Prophylaxis with Pegfilgrastim and Ciprofloxacin - Schema Supportive Care Management Filgrastim 150 µg/m 2 Days 5-10 (n=390) Breast cancer patients (n=1201) TAC Treatment (6-8 cycles) Docetaxel 75 mg/m 2 Doxorubicin 50 mg/m 2 Cyclophosphamide 500 mg/m 2 Day 1 every 3 weeks Ciprofloxacin 500 mg bid Days 5-10 (n=252) Pegfilgrastim 6 mg Day 2 (n=323) Analysis of neutropenia, infection Pegfilgrastim 6 mg Day 2 + Ciprofloxacin 500 mg bid Day 5-10 (n=236) von Minckwitz, et al. ASCO Abstract 8008
22 Primary Prophylaxis with Pegfilgrastim and Ciprofloxacin - Results Filgrastim Ciprofloxacin Pegfilgrastim Pegfilgrastim/Ciprofloxacin Incidence Per Patient, % P < Febrile Neutropenia P < Grade 3/4 Neutropenia 5 7 P < Severe Infection Von Minckwitz et al. ASCO Abstract 8008 Growth Factor Administration Pegfilgrastim 6 mg subcutaneous 1-3 days post chemotherapy Filgrastim 5mgm/kg beginning 1-3 days post chemotherapy continuing past nadir Sargramostim 250mgm/m2/day beginning 1-3 days post chemotherapy continuing post nadir NCCN Guidelines v1.2006
23 Question 2 The patient lives 30 miles from the treatment center and requests that she receive her pegfilgrastim on the same day as her chemotherapy: a. Giving chemotherapy and pegfilgrastim on the same day are of no consequence b. Pegfilgrastim should be given on day 2 following chemotherapy c. Patients should not be given any CSF since it is inconvenient Question 2 The patient lives 30 miles from the treatment center and requests that she receive her pegfilgrastim on the same day as her chemotherapy: a. Giving chemotherapy and pegfilgrastim on the same day are of no consequence b. Pegfilgrastim should be given on day 2 following chemotherapy c. Patients should not be given any CSF since it is inconvenient
24 Explanation Question 2 Arrangements should be made to give the pegfilgrastim on the day following chemotherapy. Kaufman et al. randomized patients to receive pegfilgrastim 6mg within 4 hours of their chemotherapy or approximately 24 hours after chemotherapy in patients with breast cancer receiving TAC chemotherapy. The duration of grade 4 neutropenia in cycle 1 was 2.6 days in patients receiving same day pegfilgrastim vs 1.4 days in patients whose pegfilgrastim was delayed 24 hours during cycle one. In cycle 3 it was 2.1 days vs 1.2 days. Febrile neutropenia rates were 33% in the same day group vs 11% in the 24 hour group across all cycles. Kaufman et al. San Antonio Breast Cancer Symposium Saven et al. ASCO 2006 Abstract Explanation Question 2 (continued) Saven et al. in a similar study in NHL found the mean duration of grade 4 neutropenia was.9 days longer in the same day group and FN rates were 3 vs 11%. In cycle 4 the mean duration of grade of grade 4 neutropenia was.7 days more.
25 Summary Febrile neutropenia is associated with increased morbidity and mortality Appropriate use of GSF beginning in the first cycle of chemotherapy can significantly reduce this risk Guidelines have been developed identifying appropriate utilization of GSF Future needs to directed to identifying risk factors for the development of febrile neutropenia Thank you for participating in this program. Click Claim Credit to continue to Post-test.
Clinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationMay 22, NCCN Clinical Practice Guidelines Panel: Myeloid Growth Factors
Charles Bowers, MD Clinical Research US Medical, Neupogen/Neulasta Amgen, Inc. One Amgen Center Drive Thousand Oaks, CA 91321-1799 (805) 447-0757 Cbower01@amgen.com May 22, 2017 NCCN Clinical Practice
More informationIs your patient at risk for chemotherapy-induced neutropenia? A look at formalizing risk assessment
Amgen sponsored symposium at the 2014 CAGPO Annual Meeting Is your patient at risk for chemotherapy-induced neutropenia? A look at formalizing risk assessment Welcome Krista Noonan MD, FRCPC Housekeeping
More informationNeutropenia is defined as a neutrophil count of less than 500 cells per mm3,
CHEMOTHERAPY-INDUCED NEUTROPENIA: IMPORTANT NEW DATA TO GUIDE NURSING ASSESSMENT AND MANAGEMENT Christopher R. Friese, RN, PhD, AOCN* ABSTRACT Chemotherapy-induced neutropenia is the most serious hematologic
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS
CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines
More informationCo-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia
Co-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia Authors: John H. Page, Shuling Li, Julia Molony, Romina Sosa,
More informationOriginal article. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy
Annals ofoncology 8: 7-24, 997. O 997 Kluwer Academic Publishers. Printed in the Netherlands. Original article The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy J.
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationMeet the Professor Dosing and toxicity management
Meet the Professor Dosing and toxicity management Lodovico Balducci & Catherine Terret Mrs. Marie O. 78 years Right breast tumor : 50 mm, upper outer quadrant, Node: 0 Biopsy (9 Dec 2009) Invasive ductal
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationGUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)
GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationSURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY
SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY Some Statistics Approximately 1 in 2 Canadians develop cancer 25% of Canadians die of cancer 2009: 810,000 Canadians
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationSAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationMonitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio )
Monitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio ) Heinz Ludwig Wilhelminen Cancer Research Institute c/o I
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationCanadian supportive care recommendations for the management of neutropenia in patients with cancer
PRACTICE GUIDELINE SERIES Canadian supportive care recommendations for the management of neutropenia in patients with cancer C.T. Kouroukis MD MSc,* S. Chia MD, S. Verma MD, D. Robson MD, C. Desbiens MD,
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care
Published on ASCO (https://www.asco.org) Home > ASCO Publishes "Top Five" List of Opportunities to Improve Quality and Value in Cancer Care ASCO Publishes "Top Five" List of Opportunities to Improve Quality
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationAn Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review
An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review CHRISTOPHER ADILETTA M.D., AJAZ SHAWL M.D. ST. JOSEPH S HEALTH, SYRACUSE, NY Our Patient Case We present
More informationIOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationBRAJACTTG. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationColony-stimulating factors
Colony stimulating factors page 1 APC/DTC Briefing Document Colony-stimulating factors Contents Conclusions from clinical evidence 1 Background 2 Clinical guidelines 2 Licensed indications 3 Clinical evidence
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) INDICATIONS FOR USE: INDICATION Adjuvant Treatment of High Risk Node Negative or Node Positive
More informationOncologist. The. Symptom Management and Supportive Care. Risk Models for Predicting Chemotherapy-Induced Neutropenia
The Oncologist Symptom Management and Supportive Care Risk Models for Predicting Chemotherapy-Induced Neutropenia GARY H. LYMAN, CHRISTOPHER H. LYMAN, OLAYEMI AGBOOLA, FOR THE ANC STUDY GROUP Health Services
More informationSurveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013
Surveillance after Treatment of Malignancies John M. Burke, M.D. March 2013 Disclosures Advisory Boards Spectrum Alexion Genomic Health Dendreon Seattle Genetics Learning Objectives Improve ability to
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationPACLitaxel Monotherapy 80mg/m 2 7 days
INDICATIONS FOR USE: PACLitaxel Monotherapy 80mg/m 2 7 days INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast carcinoma (mbc) in patients C50 00226a Hospital who have either
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationoriginal article introduction original article
Annals of Oncology 19: 292 298, 2008 doi:10.1093/annonc/mdm438 Published online 9 September 2007 Pegfilgrastim 6 ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide)
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide Protocol Code Tumour Group Contact Physician BRAJFEC Breast Dr. Susan Ellard ELIGIBILITY: Patients
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationAuthor's response to reviews
Author's response to reviews Title: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard
More informationMartha Trout on 6/17/2012 at Pleasant Valley Cancer Center. Jane Plummer. Tom Plummer
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More information5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy
5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Neoadjuvant treatment for breast carcinoma C50 00265a Adjuvant treatment for breast
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationGeneral Authorization Criteria for ALL Agents and Indications:
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More information